Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 10,553 matching trials from the live ClinicalTrials.gov search.

Filters: Cincinnati, Ohio Clear all

Conditions: Ulcerative Colitis and Crohn's Disease
Interventions: Vedolizumab, Other Biologic Agents; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 5,302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 66
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 54 more

Conditions: Atopic Dermatitis
Interventions: Placebo, PF-04965842, PF04965842; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 52
States / cities: Birmingham, Alabama • Madera, California • Mission Viejo, California + 31 more

Conditions: Morbid Obesity
Interventions: Not listed
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Alzheimer Disease
Interventions: AL002, Placebo; Drug
Lead sponsor: Alector Inc.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 29
States / cities: Phoenix, Arizona • Rogers, Arkansas • Costa Mesa, California + 25 more

Conditions: Malnutrition, Sarcopenia
Interventions: medical food with AN777, oral nutritional formula; Other
Lead sponsor: Abbott Nutrition; Industry
Eligibility: 65 Years to 90 Years
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: Birmington, Alabama • Santa Rosa, California • Addison, Illinois + 5 more

Conditions: Hemophilia A
Interventions: ReFacto; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 6 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 4
States / cities: Los Angeles, California • New Brunswick, New Jersey • Cincinnati, Ohio + 1 more

Conditions: Chronic Graft-versus-host-disease
Interventions: Axatilimab; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 2 Years and older
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 47
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 37 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: carmoterol (CHF 4226), salmeterol, placebo; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 24
States / cities: Jonesboro, Arkansas • Fresno, California • San Diego, California + 19 more

Conditions: Low-grade Serous Ovarian Cancer, Low-grade Serous Fallopian Tube Cancer, Low-grade Serous Peritoneal Cancer
Interventions: MEK162, MEK inhibitor; oral, Physician's choice chemotherapy; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 77
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 37 more

Conditions: Leukemia, Long-term Effects Secondary to Cancer Therapy in Children, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment
Interventions: management of therapy complications, psychosocial assessment and care; Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: 6 Years to 16 Years
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 31
States / cities: Phoenix, Arizona • Loma Linda, California • Long Beach, California + 26 more

Conditions: Psoriasis
Interventions: MEDI-522, Placebo; Drug · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 18
States / cities: Little Rock, Arkansas • Fresno, California • Vallejo, California + 15 more

Conditions: MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions: Rezdiffra, Resmetirom, ACTOS/pioglitazone, FARXIGA/dapagliflozin; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 16
States / cities: Chandler, Arizona • North Little Rock, Arkansas • Coronado, California + 12 more

Conditions: Breast Cancer
Interventions: exemestane; Drug
Lead sponsor: NCIC Clinical Trials Group; Network
Eligibility: 35 Years and older · Female only
Enrollment: 4,560 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2018
U.S. locations: 41
States / cities: Birmingham, Alabama • Anchorage, Alaska • La Jolla, California + 34 more

Conditions: Fabry Disease
Interventions: AMT-191; Drug
Lead sponsor: UniQure Biopharma B.V.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 7 more

Conditions: Urinary Incontinence
Interventions: OnabotulinumtoxinA; Biological
Lead sponsor: Allergan; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 11 more

Conditions: Chronic Graft-versus-host Disease
Interventions: Itacitinib, Placebo, Methylprednisolone, Prednisone; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 39
States / cities: Tucson, Arizona • Little Rock, Arkansas • Duarte, California + 30 more

Conditions: Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases, Neuromuscular Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn, Nervous System Diseases
Interventions: Deramiocel (CAP-1002), Placebo; Biological
Lead sponsor: Capricor Inc.; Industry
Eligibility: 10 Years and older · Male only
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 20
States / cities: Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 17 more

Conditions: Surgical Site Infection in Obese Women Undergoing C-section
Interventions: cephalexin & metronidazole, placebo; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 13 Years and older · Female only
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: HIV Infections, HIV Wasting Syndrome
Interventions: Optimune oral nutritional supplement; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 18
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 12 more

Conditions: Primary Open Angle Glaucoma (POAG)
Interventions: CyPass Micro-Stent, Cataract Surgery; Device · Procedure
Lead sponsor: Alcon Research; Industry
Eligibility: 45 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 22
States / cities: Glendale, Arizona • Fayetteville, Arkansas • La Jolla, California + 19 more

Conditions: Anaplastic Astrocytoma, Anaplastic Ependymoma, Astrocytoma, Grade II, Ependymoma, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Oligodendroglioma, Brainstem Tumors
Interventions: imetelstat sodium; Drug
Lead sponsor: Pediatric Brain Tumor Consortium; Network
Eligibility: 12 Months to 21 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 11
States / cities: Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 8 more

Conditions: Respiratory Syncytial Virus (RSV)
Interventions: RSV ΔNS2/Δ1313/I1314L Vaccine, RSV 6120/ΔNS2/1030s Vaccine, RSV 276 Vaccine, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 25 Months
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 14
States / cities: Los Angeles, California • San Diego, California • Aurora, Colorado + 10 more

Conditions: ST Elevation Myocardial Infarction, Non ST Elevation Myocardial Infarction
Interventions: Colchicine, Spironolactone, SYNERGY Bioabsorbable Polymer Drug-Eluting Stent, Colchicine-Placebo, Spironolactone-Placebo; Drug · Device
Lead sponsor: Population Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 7,264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 11
States / cities: Bakersfield, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Bevacizumab, Carboplatin, Paclitaxel; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 61
States / cities: Chandler, Arizona • Flagstaff, Arizona • Bellflower, California + 55 more

Search by objective public record fields.

Entyvio (Vedolizumab) Long Term Safety Study

JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis

Follow-up of Adolescent Bariatric Surgery

A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease

Evaluation of an Oral Nutritional Supplement Containing AN777

Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery

A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

Dose Finding Study of CHF 4226 for Treating Patients With COPD

A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer

Neurobehavioral Complications in Children Who Were Previously Treated With Steroids and Intrathecal Therapy for Acute Lymphoblastic Leukemia

Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis

Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis

Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer

Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease

A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity

GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

Use of 48 Hour Course of Antibiotics to Prevent Surgical Site Infection in Obese Patients Undergoing Cesarean Delivery

A Study to Evaluate High Protein Supplementation in HIV-Positive Patients With Stable Weight Loss

A Study to Assess Long-Term Safety of the CyPass Micro-Stent in Patients Completing the COMPASS Trial

Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors

Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)